Search Results
Search for other papers by Ruth Therese Casey in
Google Scholar
PubMed
Search for other papers by Deborah Saunders in
Google Scholar
PubMed
Search for other papers by Benjamin George Challis in
Google Scholar
PubMed
Search for other papers by Deborah Pitfield in
Google Scholar
PubMed
Search for other papers by Heok Cheow in
Google Scholar
PubMed
Search for other papers by Ashley Shaw in
Google Scholar
PubMed
Search for other papers by Helen Lisa Simpson in
Google Scholar
PubMed
Context
Multiple endocrine neoplasia type 1 (MEN1) is a hereditary condition characterised by the predisposition to hyperplasia/tumours of endocrine glands. MEN1-related disease, moreover, malignancy related to MEN1, is increasingly responsible for death in up to two-thirds of patients. Although patients undergo radiological and biochemical surveillance, current recommendations for radiological monitoring are based on non-prospective data with little consensus or evidence demonstrating improved outcome from this approach. Here, we sought to determine whether cumulative radiation exposure as part of the recommended radiological screening programme posed a distinct risk in a cohort of patients with MEN1.
Patients and study design
A retrospective review of 43 patients with MEN1 attending our institution between 2007 and 2015 was performed. Demographic and clinical information including phenotype was obtained for all patients. We also obtained details regarding all radiological procedures performed as part of MEN1 surveillance or disease localisation. An estimated effective radiation dose (ED) for each individual patient was calculated.
Results
The mean ED for the total patient cohort was 121 mSv, and the estimated mean lifetime risk of cancer secondary to radiation exposure was 0.49%. Patients with malignant neuroendocrine tumours (NETS) had significantly higher ED levels compared to patients without metastatic disease (P < 0.0022).
Conclusions
In MEN1, radiological surveillance is associated with clinically significant exposure to ionising radiation. In patients with MEN1, multi-modality imaging strategies designed to minimise this exposure should be considered.
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
IMED Biotech Unit, Clinical Discovery Unit, AstraZeneca, UK
Search for other papers by Benjamin G Challis in
Google Scholar
PubMed
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by Andrew S Powlson in
Google Scholar
PubMed
Search for other papers by Ruth T Casey in
Google Scholar
PubMed
Search for other papers by Carla Pearson in
Google Scholar
PubMed
Search for other papers by Brian Y Lam in
Google Scholar
PubMed
Search for other papers by Marcella Ma in
Google Scholar
PubMed
Search for other papers by Deborah Pitfield in
Google Scholar
PubMed
Search for other papers by Giles S H Yeo in
Google Scholar
PubMed
Search for other papers by Edmund Godfrey in
Google Scholar
PubMed
Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by Heok K Cheow in
Google Scholar
PubMed
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by V Krishna Chatterjee in
Google Scholar
PubMed
Search for other papers by Nicholas R Carroll in
Google Scholar
PubMed
Search for other papers by Ashley Shaw in
Google Scholar
PubMed
Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by John R Buscombe in
Google Scholar
PubMed
Search for other papers by Helen L Simpson in
Google Scholar
PubMed
Objective
In adults with hyperinsulinaemic hypoglycaemia (HH), in particular those with insulinoma, the optimal diagnostic and management strategies remain uncertain. Here, we sought to characterise the biochemical and radiological assessment, and clinical management of adults with HH at a tertiary centre over a thirteen-year period.
Design
Clinical, biochemical, radiological and histological data were reviewed from all confirmed cases of adult-onset hyperinsulinaemic hypoglycaemia at our centre between 2003 and 2016. In a subset of patients with stage I insulinoma, whole-exome sequencing of tumour DNA was performed.
Results
Twenty-nine patients were identified (27 insulinoma, including 6 subjects with metastatic disease; 1 pro-insulin/GLP-1 co-secreting tumour; 1 activating glucokinase mutation). In all cases, hypoglycaemia (glucose ≤2.2 mmol/L) was achieved within 48 h of a supervised fast. At fast termination, subjects with stage IV insulinoma had significantly higher insulin, C-peptide and pro-insulin compared to those with insulinoma staged I–IIIB. Preoperative localisation of insulinoma was most successfully achieved with EUS. In two patients with inoperable, metastatic insulinoma, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE rapidly restored euglycaemia and lowered fasting insulin. Finally, in a subset of stage I insulinoma, whole-exome sequencing of tumour DNA identified the pathogenic Ying Yang-1 (YY1) somatic mutation (c.C1115G/p.T372R) in one tumour, with all tumours exhibiting a low somatic mutation burden.
Conclusion
Our study highlights, in particular, the utility of the 48-h fast in the diagnosis of insulinoma, EUS for tumour localisation and the value of PRRT therapy in the treatment of metastatic disease.